Abstract
There is a strong impetus in the psychosis research field to develop interventions that aim to prevent the onset of psychotic disorders. Over the past 15 years there has been a tremendous development in the work aimed at understanding the pre-psychotic period. More recently there has been a focus on developing and testing treatments both pharmacological and psychological that could potentially prevent or delay the onset of psychosis. One of the psychological treatments that has received the most attention is cognitive behavioral therapy (CBT). Relatively few trials have been completed and this paper reviews the existing trials. Implications of these trials for the treatment of this early phase as well as for designing future studies are discussed.
Keywords: Cognitive behavioral therapy, prodromal psychosis, psychotic disorders, pre-psychotic period, ultra-high-risk criteria (UHR), Comprehensive Assessment of At Risk Mental State (CAARMS), antipsychotics, stress management, attenuated symptoms, psychological treatments
Current Pharmaceutical Design
Title: Cognitive Behavioral Therapy in Prodromal Psychosis
Volume: 18 Issue: 4
Author(s): Jean Addington, Catherine Marshall and Paul French
Affiliation:
Keywords: Cognitive behavioral therapy, prodromal psychosis, psychotic disorders, pre-psychotic period, ultra-high-risk criteria (UHR), Comprehensive Assessment of At Risk Mental State (CAARMS), antipsychotics, stress management, attenuated symptoms, psychological treatments
Abstract: There is a strong impetus in the psychosis research field to develop interventions that aim to prevent the onset of psychotic disorders. Over the past 15 years there has been a tremendous development in the work aimed at understanding the pre-psychotic period. More recently there has been a focus on developing and testing treatments both pharmacological and psychological that could potentially prevent or delay the onset of psychosis. One of the psychological treatments that has received the most attention is cognitive behavioral therapy (CBT). Relatively few trials have been completed and this paper reviews the existing trials. Implications of these trials for the treatment of this early phase as well as for designing future studies are discussed.
Export Options
About this article
Cite this article as:
Addington Jean, Marshall Catherine and French Paul, Cognitive Behavioral Therapy in Prodromal Psychosis, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316082
DOI https://dx.doi.org/10.2174/138161212799316082 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Momordica charantia and Type 2 Diabetes: From in vitro to Human Studies
Current Diabetes Reviews Increased Fetal Cardiovascular Disease Risk: Potential Synergy Between Gestational Diabetes Mellitus and Maternal Hypercholesterolemia
Current Vascular Pharmacology Plant Substances as Antiviral Agents: An Update (1997-2001)
Current Organic Chemistry Targeting the Platelet Integrin GPIIb/IIIa
Current Pharmaceutical Design MicroRNA and Cancer: Tiny Molecules with Major Implications
Current Genomics Towards the Molecular Foundations of Glutamatergic-targeted Antidepressants
Current Neuropharmacology The Role for Oxidative Stress in Aberrant DNA Methylation in Alzheimer’s Disease
Current Alzheimer Research Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Metabolic Syndrome - Risk Factors for Atherosclerosis and Diabetes
Current Diabetes Reviews The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells
Current Medicinal Chemistry - Anti-Cancer Agents GH-Inhibitory Activity of Novel Somatostatin Agonists: Potential Applications in Acromegaly
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Depression and Disturbed Bone Metabolism: A Narrative Review of the Epidemiological Findings and Postulated Mechanisms
Current Molecular Medicine New Trends in Fiber-Optic Chemical and Biological Sensors
Current Analytical Chemistry Aberrant DNA Methylation and Prostate Cancer
Current Genomics Painful Peripheral Neuropathies
Current Neuropharmacology T Cell Tuning for Tumour Therapy: Enhancing Effector Function and Memory Potential of Therapeutic T cells
Current Gene Therapy Cardiovascular Involvement in Pediatric Systemic Autoimmune Diseases: The Emerging Role of Noninvasive Cardiovascular Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Mechanistic Insights into the Antileukemic Activity of Hyperforin
Current Cancer Drug Targets Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology